×
About 212,163 results

Fluconazole - fluconazole tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11e0926-cd15-49ba-b0ee-2b6d4e009dd8

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

Ascor - ascorbic acid injection-McGuff Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306

Oct 1st, 2022 - ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy. ASCOR is vitamin C indicated for the short...

Bimatoprost - bimatoprost solution/ drops-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac853f64-50bd-4bff-9cbe-aac93ef5550f

Jul 1st, 2022 - Bimatoprost ophthalmic solution, 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. (1) Bimatoprost ophthalmic solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Moxifloxacin - moxifloxacin solution/ drops-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae77e219-8af9-4aa4-96d3-05c9726a1d3c

Jun 6th, 2022 - Moxifloxacin ophthalmic solution, 0.5% is a topical fluoroquinolone anti- infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumonia...

Procentra - dextroamphetamine sulfate solution-Independence Pharmaceuticals, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1548cce2-fb6b-4f17-8a3b-868933f6c9d6

Jun 1st, 2022 - ProCentra ® (dextroamphetamine sulfate) Oral Solution is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following gr...

Quetiapine fumarate - quetiapine fumarate tablet, extended release-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7803a290-91c0-4e7f-90b5-d2ff33a46cee

Jun 1st, 2022 - Quetiapine extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3) Quetiapine extended-release tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine ext...

Imatinib mesylate - imatinib mesylate tablet, film coated-Apotex Corp
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509

May 30th, 2022 - Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon...

Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection
https://www.sciencedirect.com/science/article/pii/S155541552100547X
The Journal for Nurse Practitioners; Pinto MD, .

Feb 7th, 2022 - Postacute sequelae of SARS-CoV2 (PASC) infection is an emerging global health crisis, variably affecting millions worldwide. PASC has no established treatment. We describe 2 cases of PASC in response to opportune administration of over-the-counter antihistamines, with significant improvement in symptoms and ability to perform activities of daily living. Future studies are warranted to understan...

The relationship of obesity and obstructive sleep apnea to the development of sarcoidos...
https://doi.org/10.1016/j.chest.2022.05.008
Chest Judson MA, Tiwari A et. al.

May 22nd, 2022 - Previous studies have demonstrated an association between body mass index (BMI) and the development of sarcoidosis. We investigated this association and the association between obstructive sleep apnea (OSA) and the development of sarcoidosis in a US Veterans Administration database. Is the presence of OSA or the BMI associated with the development of sarcoidosis over the subsequent 12 months? W...

Brain uptake and distribution patterns of 2-hydroxypropyl-ß-cyclodextrin after intrathe...
https://doi.org/10.1093/jpp/rgac001
The Journal of Pharmacy and Pharmacology; Banks WA, Calias P et. al.

May 22nd, 2022 - Cyclodextrins are increasingly used therapeutically. For example, 2-hydroxypropyl-ß-cyclodextrin (kleptose) is used for the treatment of Niemann-Pick disease. Kleptose crosses the blood-brain barrier poorly, in part because of a central nervous system (CNS)-to-blood (efflux) transporter, and so is administered by the intrathecal (IT) route in the treatment of Niemann-Pick disease. Here, we eval...

Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
https://doi.org/10.1016/S1473-3099(22)00221-3
The Lancet. Infectious Diseases; Lo NC, Bezerra FSM et. al.

May 21st, 2022 - Schistosomiasis is a helminthiasis infecting approximately 250 million people worldwide. In 2001, the World Health Assembly (WHA) 54.19 resolution defined a new global strategy for control of schistosomiasis through preventive chemotherapy programmes. This resolution culminated in the 2006 WHO guidelines that recommended empirical treatment by mass drug administration with praziquantel, predomi...

Testicular androgens determining the incidence of spike-wave discharges in taiep rats: ...
https://doi.org/10.1016/j.neulet.2022.136684
Neuroscience Letters; Carmen C, Ibarra-Hernández Juan M et. al.

May 21st, 2022 - Absence seizures are characterized as a generalized type of epilepsy that occurs during childhood. Importantly, absence seizures in children often discontinue after puberty. There is limited availability of animal models in which electroencephalography (EEG) can be performed in the long term; however, two absence seizure models, GAERS and WAG/Rij albino rats, are available. The taiep rat is a m...

Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DN...
https://doi.org/10.1111/bjh.18230
British Journal of Haematology; Peng F, Wang Y et. al.

May 21st, 2022 - The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we evaluated the efficacy of this approach using a xenograft model. Tumour growth was significantly delayed in mice treated with single electroporation-enh...

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Amb...
https://doi.org/10.1016/j.clml.2022.04.012
Clinical Lymphoma, Myeloma & Leukemia; Nasta SD, Hughes ME et. al.

May 21st, 2022 - Chimeric antigen receptor T-cell therapy (CAR T) is a revolutionary adoptive immunotherapy approach in lymphoma; however, substantial resources are necessary for administration and care of these patients. Our institution has administered tisagenlecleucel primarily in an outpatient setting, and here we report our clinical outcomes. We conducted a single institution, retrospective study investiga...

FDA Roundup: May 20, 2022 | FDA
https://www.fda.gov/news-events/press-announcements/fda-roundup-may-20-2022

May 20th, 2022 - For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On May 19, the FDA issued responses to two food additive petitions and a citizen petition requesting agency action on phthalates in food contact applications. The FDA amended its food additive regulations to no longer provide for most phthalates to...

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03412877

May 20th, 2022 - Background: The administration of autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of participants with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique mutated neoantigens expressed by the cancer not shared by other melanomas. Administration of bulk autologous TIL to participants with a variety of ot...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

May 20th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myeloma when used in conjunction with granulocyte-colony stimulating factor (G-CSF). The drug s mechanism of action is the specific and reversible inhibit...

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
https://clinicaltrials.gov/ct2/show/NCT04766723

May 20th, 2022 - The purpose of this study is to determine whether a single treatment with administration of NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. Th...

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

May 20th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but more common in the relapsed/refractory population due to its poor prognosis and response to standard purine analog chemotherapy. HCLv cells are CD25-neg...

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04915183

May 20th, 2022 - Study Description: Individuals undergoing cisplatin-based chemoradiation therapy are at risk for developing significant, permanent hearing loss. The cholesterol-lowering drug atorvastatin has the potential to reduce the incidence and severity of hearing loss, as evidenced by our preclinical data in mice and our retrospective data in humans.Here we will compare hearing changes between subjects o...